Short answer
Voyager Therapeutics, Inc. (VYGR) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial and operating results released August 6, 2026.
Voyager Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial and operating results released August 6, 2026
- Press release contains the substantive results and operating updates
- CEO Alfred Sandrock signed the filing as principal executive officer
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 net loss $24.5M, or $0.40 per share, improved from $33.4M and $0.57 year over year
- Cash, equivalents and marketable securities $148.8M, funding planned operations into 2028 under current plans
- VY1706 FDA-cleared trial expected to begin dosing early Alzheimer’s patients in Q4 2026
- VY7523 tau PET efficacy data expected in Q4 2026, creating a key clinical readout
- VY1706 preclinical data showed sustained tau reduction up to 75% in key Alzheimer’s brain regions after one IV dose
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Voyager Therapeutics, Inc. 8-K filings
Get the next VYGR 8-K as it lands
Follow VYGR for push alerts, or ask the research agent what this filing means.